An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT07696377 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Obinutuzumab β

Interventions

DRUG: Obinutuzumab β

Sponsor

Zhongming Qiu